AstraZeneca Partners with Revna Biosciences to Enhance Epidermal Growth Factor Receptor (EGFR) Biomarker Testing in Ghana ...

Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer ...

The drug receives conditional marketing authorization by the CHMP for the treatment of HER2-positive biliary tract cancer.

Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal ...

Roche announces EMA committee recommends EU label update for its Phesgo to allow administration outside of clinical settings: Basel Friday, May 2, 2025, 12:00 Hrs [IST] Roche anno ...

A new topical gel called LUT014 successfully reduced the severity of a painful acne‐like rash that commonly occurs as a side effect of targeted therapy with epidermal growth factor receptor (EGFR) ...

ORIC Pharmaceuticals, Inc.’s ORIC share price has surged by 7.27%, which has investors questioning if this is right time to ...

Mersana Therapeutics, Inc.’s MRSN share price has dipped by 8.13%, which has investors questioning if this is right time to ...

This collaboration will provide early-stage HER2-positive breast cancer patients with access to the targeted therapy that can ...

Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and safety of Phesgo's ...

The use of an investigational topical BRAF-inhibiting gel appeared to be effective in treating acneiform rash in patients ...